Literature DB >> 28017775

The network of immunosuppressive pathways in glioblastoma.

Davide Mangani1, Michael Weller2, Patrick Roth3.   

Abstract

Glioblastoma remains a fatal tumor despite increased knowledge regarding the complex signalling pathways that drive this devastating disease. Recently, immunotherapeutic approaches have shown remarkable and durable responses in various cancers including metastatic melanoma and advanced non-small cell lung cancer. So far, it remains unclear whether these immunotherapeutics may also work against glioblastoma and other tumors residing in the central nervous system. It is well known that patients with glioblastoma suffer from profound local immunosuppression that represents the major hurdle to overcome in the context of immunotherapy. Several studies have demonstrated that this immunosuppressive phenotype is orchestrated by glioma-derived membrane-bound and soluble factors as well as the particular microenvironment within the brain. Here, we discuss the molecular and cellular pathways involved in glioblastoma-mediated inhibition of the immune system and highlight possible treatment approaches aiming at reinvigorating anti-tumor immune responses.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood brain barrier; Glioblastoma; Immune checkpoints; Immunosuppression; Immunotherapy; Molecular and cellular mechanisms

Mesh:

Year:  2016        PMID: 28017775     DOI: 10.1016/j.bcp.2016.12.011

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  37 in total

Review 1.  The Gut-Brain Axis, Paving the Way to Brain Cancer.

Authors:  Ruty Mehrian-Shai; Juergen K V Reichardt; Curtis C Harris; Amos Toren
Journal:  Trends Cancer       Date:  2019-03-16

2.  Glioma escape signature and clonal development under immune pressure.

Authors:  Cecile L Maire; Malte Mohme; Michael Bockmayr; Krystian D Fita; Kristoffer Riecken; Daniela Börnigen; Malik Alawi; Antonio Failla; Katharina Kolbe; Svenja Zapf; Mareike Holz; Katrin Neumann; Lasse Dührsen; Tobias Lange; Boris Fehse; Manfred Westphal; Katrin Lamszus
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

3.  Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines.

Authors:  Lei Zhang; John S Yu
Journal:  J Neurooncol       Date:  2019-05-31       Impact factor: 4.130

Review 4.  The Role of Checkpoint Inhibitors in Glioblastoma.

Authors:  Kunal Desai; Anne Hubben; Manmeet Ahluwalia
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

Review 5.  Altered nutrient status reprograms host inflammation and metabolic health via gut microbiota.

Authors:  Rachel M Golonka; Xia Xiao; Ahmed A Abokor; Bina Joe; Matam Vijay-Kumar
Journal:  J Nutr Biochem       Date:  2020-02-22       Impact factor: 6.048

Review 6.  Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Authors:  Michael Weller; Patrick Roth; Matthias Preusser; Wolfgang Wick; David A Reardon; Michael Platten; John H Sampson
Journal:  Nat Rev Neurol       Date:  2017-05-12       Impact factor: 42.937

7.  Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.

Authors:  Katarzyna C Pituch; Jason Miska; Giedre Krenciute; Wojciech K Panek; Gina Li; Tania Rodriguez-Cruz; Meijing Wu; Yu Han; Maciej S Lesniak; Stephen Gottschalk; Irina V Balyasnikova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

8.  Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.

Authors:  David Xu; Donghui Zhou; Khuchtumur Bum-Erdene; Barbara J Bailey; Kamakshi Sishtla; Sheng Liu; Jun Wan; Uma K Aryal; Jonathan A Lee; Clark D Wells; Melissa L Fishel; Timothy W Corson; Karen E Pollok; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2020-05-21       Impact factor: 5.100

9.  RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.

Authors:  Stephen J Bagley; Wei-Ting Hwang; Steven Brem; Gerald P Linette; Donald M O'Rourke; Arati S Desai
Journal:  J Neurooncol       Date:  2018-10-23       Impact factor: 4.130

10.  Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial.

Authors:  Nan Ji; Yang Zhang; Yunpeng Liu; Jian Xie; Yi Wang; Shuyu Hao; Zhixian Gao
Journal:  JCI Insight       Date:  2018-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.